Treatment of Tuberculosis — Adjuvant Therapies to Increase the Efficiency of Antibiotics
There is growing evidence that resistance to Mycobacterium tuberculosis infection is governed in large part by the regulation of host cell death. Lipid mediators called eicosanoids are thought to play a central role in this process. The subject invention is a novel method of enhancing the efficacy of antibiotic treatments for Mycobacterium tuberculosis infection by co-administering an inhibitor of 5-lipoxygenase and a COX-2 dependent prostaglandin. Inhibition of 5-lipoxygenase and treatment with prostaglandin E2 results in alteration of the eicosanoid balance. The synergistic effects of altering the eicosanoid balance and treatment with antibiotics is believed to result in more efficient reduction of the bacterial burden and thus, the period of antibiotic administration and antibiotic dosage could potentially be reduced. In vivo data from mouse models can be provided upon request.
|Potential Commercial Applications:||Competitive Advantages:||An adjuvant therapy for existing antibiotic treatment regiments against tuberculosis.||Increase the efficacy of existing antibiotic treatments for tuberculosis, potentially reducing both the duration and dosage of the antibiotic treatment.|
Katrin Mayer (NIAID)
Bruno Bezerril Andrade (NIAID)
F. Alan Sher (NIAID)
Daniel Barber (NIAID)
US Application No. 61/515,229
US Application No. 61/515,237
PCT Application No. PCT/US2012/049280
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize adjuvant therapy for antibiotic treatment regiments against tuberculosis. For collaboration opportunities, please contact Katrin Mayer. Ph.D. at firstname.lastname@example.org or 301-594-8061.
Kevin Chang , Ph.D.
NIH Office of Technology Transfer
OTT Reference No: E-189-2011/0